Dentsply Sirona Appoints Daniel Scavilla as Chief Executive Officer
Provides Select Preliminary Second Quarter 2025 Results and Reaffirms 2025 OutlookCHARLOTTE, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA...
Day: July 21, 2025
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
- New board members bring decades of experience in company building, corporate strategy, commercialization, and business development CAMBRIDGE, Mass., July...
Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025
Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025 Gdańsk, Poland -...
Profusa Announces $100 Million Equity Line of Credit to Initiate Bitcoin Treasury Strategy
BERKELEY, Calif, July 21, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital...
Globus Medical Announces Leadership Transitions and Preliminary Second Quarter 2025 Sales Results
AUDUBON, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced...
UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Findings published in the journal of Clinical Genitourinary Cancer show patients remained event-free for a median of two years after...
Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110
CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on...
Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference – The Sildenafil Cream That Raises the Bar
A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra® for men - in a proprietary...
Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025
WATERTOWN, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,...
ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026
Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE,...
NKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative Diseases
Troculeucel, a cryopreserved, autologous enhanced natural killer cell therapy, has demonstrated preliminary clinical benefit without any drug-related adverse events in...
Expanding Analyst Interest in ORYZON
New U.S. investment bank joins, bringing total coverage to ten analystsMADRID and CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) --...
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease
FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s DiseaseCAMBRIDGE, Mass., July 21,...
Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025
Conference call scheduled for 4:30 p.m. Eastern TimeWALTHAM, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a...
ProPhase Labs Board of Directors Authorizes Management to Explore Strategic Reverse Merger and Approves Crypto Treasury Initiative
UNIONDALE, NY, July 21, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation...
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease
FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s Disease CAMBRIDGE, Mass., July...
ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress
WESTON, Fla., July 21, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company...
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal”) (Nasdaq: AMRX) announced that its subsidiary, Amneal Pharmaceuticals...
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results
– Results Reflect Continued Financial Strength and Deleveraging – BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc....
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease
In Vitro Experiments Showing Protection of Neurons under Disease Conditions Support Proteomics Biomarker Analysis from Phase 2 SEQUEL StudyPITTSBURGH, July...